![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, August 03, 2003 9:53:54 PM
My dumb question for the day. (well at least here!)
If so many promising drugs have washed out in clinical trials after millions have been spent to get them to those clinical trial, will drug companies be willing to have an outside party examine the sample groups to determine common factors in the failure vs sucess of the test? Now granted in some cases of drug testing the dna required may not have been collected, but those surviving patients might be available for sample collection. I can't put my finger on a number for drugs that fail in the finals, but I imagine it's a few thousand a year. Does DNAP have any attraction to those drug developers as a possible salvation of all that development cost?
Question was not posed to Mingwan alone. He just deserved special mention for sharing so much with those of us who are not up to his speed on technical due dilligence. In my situation I think it's a case of artificial intelligence versus natural stupidity!
Stakddek
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM